{"id":65189,"date":"2026-05-13T22:09:05","date_gmt":"2026-05-13T14:09:05","guid":{"rendered":"https:\/\/flcube.com\/?p=65189"},"modified":"2026-05-13T22:09:06","modified_gmt":"2026-05-13T14:09:06","slug":"bio-theras-cd25-targeted-adc-bat8013-receives-nmpa-approval-for-advanced-solid-tumor-clinical-studies-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65189","title":{"rendered":"Bio-Thera&#8217;s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China"},"content":{"rendered":"\n<p><strong>Bio-Thera Solutions Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688177:SHA\">SHA: 688177<\/a>) announced that its <strong>CD25-targeted antibody drug conjugate (ADC) BAT8013<\/strong> has received approval from China&#8217;s National Medical Products Administration (NMPA) to proceed with <strong>clinical studies<\/strong> in <strong>advanced or metastatic solid tumors<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-amp-mechanism-milestone\">Development &amp; Mechanism Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Bio-Thera Solutions Ltd. (SHA: 688177)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>BAT8013<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>CD25-targeted antibody drug conjugate (ADC)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced or metastatic solid tumors<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>CD25 (IL-2 receptor alpha chain)<\/td><\/tr><tr><td><strong>Payload<\/strong><\/td><td>Exatecan (topoisomerase I inhibitor)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Clinical study approval granted<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-dual-action-mechanism-of-action\">Dual-Action Mechanism of Action<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-targeted-delivery-system\">Targeted Delivery System<\/h3>\n\n\n\n<p>BAT8013 employs a sophisticated <strong>receptor-mediated delivery mechanism<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Specific binding<\/strong>: Antibody component selectively binds to <strong>CD25 on cell surface<\/strong><\/li>\n\n\n\n<li><strong>Cellular internalization<\/strong>: Complex enters target cells via <strong>receptor-mediated endocytosis<\/strong><\/li>\n\n\n\n<li><strong>Controlled payload release<\/strong>: In lysosomal environment, <strong>cathepsin enzymes cleave the linker<\/strong>, releasing cytotoxic payload Exatecan<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-cytotoxic-payload-activity\">Cytotoxic Payload Activity<\/h3>\n\n\n\n<p><strong>Exatecan<\/strong>, a potent <strong>topoisomerase I inhibitor<\/strong>, executes dual anti-tumor effects:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>DNA damage induction<\/strong>: Causes accumulation of <strong>single-strand DNA breaks<\/strong><\/li>\n\n\n\n<li><strong>Replication catastrophe<\/strong>: Single-strand breaks convert to <strong>lethal double-strand breaks during DNA replication<\/strong><\/li>\n\n\n\n<li><strong>Apoptotic triggering<\/strong>: Irreparable DNA damage initiates programmed cell death<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-dual-therapeutic-impact\">Dual Therapeutic Impact<\/h3>\n\n\n\n<p>The unique mechanism delivers <strong>simultaneous immunomodulatory and direct cytotoxic effects<\/strong>:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Effect<\/th><th>Mechanism<\/th><th>Therapeutic Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Treg Depletion<\/strong><\/td><td>Selective elimination of CD25+ regulatory T cells (Tregs) in tumor microenvironment<\/td><td>Reversal of immunosuppressive tumor milieu, enhanced anti-tumor immunity<\/td><\/tr><tr><td><strong>Direct Tumor Killing<\/strong><\/td><td>Cytotoxic payload delivery to CD25+ tumor cells<\/td><td>Direct elimination of malignant cells expressing CD25<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-development-rationale\">Strategic Development Rationale<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-target-selection-rationale\">Target Selection Rationale<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CD25 Expression Profile<\/strong>: Overexpressed on both <strong>regulatory T cells<\/strong> and certain <strong>tumor cell populations<\/strong><\/li>\n\n\n\n<li><strong>Immunosuppressive Role<\/strong>: Tregs expressing CD25 create immune-evasive microenvironment in solid tumors<\/li>\n\n\n\n<li><strong>Therapeutic Window<\/strong>: Differential expression patterns may provide selectivity between normal and malignant tissues<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-differentiation\">Competitive Differentiation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual-mechanism approach<\/strong>: Combines direct cytotoxicity with immune microenvironment modulation<\/li>\n\n\n\n<li><strong>Novel target application<\/strong>: CD25-targeted ADC represents innovative application beyond traditional immune checkpoint targets<\/li>\n\n\n\n<li><strong>Payload optimization<\/strong>: Exatecan&#8217;s mechanism provides potent cytotoxic activity with established clinical precedent<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-pipeline-positioning\">Market Context &amp; Pipeline Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Market Expansion<\/strong>: Global ADC market continues rapid growth with <strong>novel targets and payloads<\/strong> driving innovation<\/li>\n\n\n\n<li><strong>Solid Tumor Challenge<\/strong>: Advanced\/metastatic solid tumors represent significant unmet medical need despite recent therapeutic advances<\/li>\n\n\n\n<li><strong>Chinese Biotech Leadership<\/strong>: Bio-Thera exemplifies China&#8217;s evolution toward <strong>innovative biologics development<\/strong> with global relevance<\/li>\n\n\n\n<li><strong>Immunotherapy Evolution<\/strong>: Next-generation approaches focus on <strong>modulating tumor microenvironment<\/strong> while delivering direct cytotoxic effects<\/li>\n<\/ul>\n\n\n\n<p>The BAT8013 program represents a <strong>strategic expansion<\/strong> of Bio-Thera&#8217;s oncology pipeline into novel ADC territory, leveraging the company&#8217;s expertise in antibody engineering and targeted therapeutics.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development and therapeutic potential for BAT8013. Actual results may differ due to risks including clinical trial outcomes, safety profile, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688177_20260513_CZWM.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688177_20260513_CZWM.\"><\/object><a id=\"wp-block-file--media-5a99a997-a03f-492b-a766-7b08fa5aecf3\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688177_20260513_CZWM.pdf\">688177_20260513_CZWM<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688177_20260513_CZWM.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5a99a997-a03f-492b-a766-7b08fa5aecf3\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Bio-Thera Solutions Ltd. (SHA: 688177) announced that its CD25-targeted antibody drug conjugate (ADC) BAT8013 has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[289,1055],"class_list":["post-65189","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-bio-thera-solutions","tag-sha-688177"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bio-Thera&#039;s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bio-Thera Solutions Ltd. (SHA: 688177) announced that its CD25-targeted antibody drug conjugate (ADC) BAT8013 has received approval from China&#039;s National Medical Products Administration (NMPA) to proceed with clinical studies in advanced or metastatic solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65189\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-Thera&#039;s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China\" \/>\n<meta property=\"og:description\" content=\"Bio-Thera Solutions Ltd. (SHA: 688177) announced that its CD25-targeted antibody drug conjugate (ADC) BAT8013 has received approval from China&#039;s National Medical Products Administration (NMPA) to proceed with clinical studies in advanced or metastatic solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65189\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T14:09:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-13T14:09:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65189#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65189\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bio-Thera&#8217;s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China\",\"datePublished\":\"2026-05-13T14:09:05+00:00\",\"dateModified\":\"2026-05-13T14:09:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65189\"},\"wordCount\":457,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Bio-Thera Solutions\",\"SHA: 688177\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65189#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65189\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65189\",\"name\":\"Bio-Thera's CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-13T14:09:05+00:00\",\"dateModified\":\"2026-05-13T14:09:06+00:00\",\"description\":\"Bio-Thera Solutions Ltd. (SHA: 688177) announced that its CD25-targeted antibody drug conjugate (ADC) BAT8013 has received approval from China's National Medical Products Administration (NMPA) to proceed with clinical studies in advanced or metastatic solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65189#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65189\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65189#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-Thera&#8217;s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bio-Thera's CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China - Insight, China&#039;s Pharmaceutical Industry","description":"Bio-Thera Solutions Ltd. (SHA: 688177) announced that its CD25-targeted antibody drug conjugate (ADC) BAT8013 has received approval from China's National Medical Products Administration (NMPA) to proceed with clinical studies in advanced or metastatic solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65189","og_locale":"en_US","og_type":"article","og_title":"Bio-Thera's CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China","og_description":"Bio-Thera Solutions Ltd. (SHA: 688177) announced that its CD25-targeted antibody drug conjugate (ADC) BAT8013 has received approval from China's National Medical Products Administration (NMPA) to proceed with clinical studies in advanced or metastatic solid tumors.","og_url":"https:\/\/flcube.com\/?p=65189","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-13T14:09:05+00:00","article_modified_time":"2026-05-13T14:09:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65189#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65189"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bio-Thera&#8217;s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China","datePublished":"2026-05-13T14:09:05+00:00","dateModified":"2026-05-13T14:09:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65189"},"wordCount":457,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Bio-Thera Solutions","SHA: 688177"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65189#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65189","url":"https:\/\/flcube.com\/?p=65189","name":"Bio-Thera's CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-13T14:09:05+00:00","dateModified":"2026-05-13T14:09:06+00:00","description":"Bio-Thera Solutions Ltd. (SHA: 688177) announced that its CD25-targeted antibody drug conjugate (ADC) BAT8013 has received approval from China's National Medical Products Administration (NMPA) to proceed with clinical studies in advanced or metastatic solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65189#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65189"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65189#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bio-Thera&#8217;s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65189"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65189\/revisions"}],"predecessor-version":[{"id":65192,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65189\/revisions\/65192"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}